Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Astrazeneca Plc Ord (OP: AZNCF ) 147.37 UNCHANGED Streaming Delayed Price Updated: 11:50 AM EDT, Oct 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Astrazeneca Plc Ord < Previous 1 2 3 4 5 6 7 8 Next > Japan Approves AstraZeneca's Two Treatments For Asthma, Rare Form Of Cancer September 27, 2022 Via Benzinga AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med September 23, 2022 Via Benzinga With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma September 21, 2022 Via Benzinga AstraZeneca's Asthma Treatment Scores European Approval September 21, 2022 Via Benzinga AstraZeneca's COVID-19 Antibody Treatment Scores Approval In Europe September 20, 2022 Via Benzinga AstraZeneca's COVID-19 Antibody Cocktail, RSV Treatment For Infants Gets European Authority Backing September 16, 2022 Via Benzinga AstraZeneca's Blood Clot Treatment Hits Primary Goal In Rare Blood Disorder Trial September 16, 2022 Via Benzinga Top Financial Stories Tuesday, September 13: Elon Musk's Takeover Set To Get Twitter Shareholder Approval, Intel Slashes Mobileye IPO Valuation, Goldman Sachs To Layoff About 500 Jobs And More... September 13, 2022 Wall Street Journal Via Benzinga US Judge Dismisses Shareholder Lawsuit Over AstraZeneca's COVID-19 Vaccine Disclosures: Report September 13, 2022 Via Benzinga AstraZeneca-Merck's Lynparza Treatment Shows Long-Term Survival In Ovarian Cancer September 09, 2022 Via Benzinga AstraZeneca Imfinzi Combo Scores FDA Approval As First Immunotherapy Regimen For Biliary Tract Cancer September 06, 2022 Via Benzinga AstraZeneca Scores Its First Global Approval For Antibody Evusheld As COVID-19 Treatment August 30, 2022 Via Benzinga Valneva Posts Additional Encouraging Data From COVID-19 Booster Trial August 29, 2022 Via Benzinga AstraZeneca Touts Positive Farxiga Data, Seeks Label Expansion In Heart Failure August 29, 2022 AstraZeneca Plc (NASDAQ: AZN) laid out the details of the Farxiga's performance in another heart failure patient population at the European Society of Cardiology Congress. Via Benzinga Back-To-Back Three Japanese Approvals For AstraZeneca's Rare Disease Treatments August 25, 2022 Via Benzinga AstraZeneca's CEO Says There Are No COVID Regrets, Looks For Oncology Acquisitions August 24, 2022 In a Reuters report, AstraZeneca Plc's (NASDAQ: Via Benzinga AstraZeneca Slaps Lawsuit Against Former Employee As He Moves To Close Rival: Report August 17, 2022 Via Benzinga UK Government Will Not Buy More AstraZeneca's COVID-19 Treatment August 16, 2022 Via Benzinga AstraZeneca-Merck's Prostate Cancer Drug Under FDA Priority Review For Expanded Use August 16, 2022 Via Benzinga AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study August 15, 2022 Via Benzinga Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation August 12, 2022 Via Benzinga AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients August 09, 2022 Via Benzinga AstraZeneca's Tagrisso Doublet Therapy Shows 49% Response Rate In Lung Cancer Setting August 08, 2022 Via Benzinga Pieris Stops Work On Cancer Med, Tested In Combo With Eli Lilly Drugs August 04, 2022 Via Benzinga AstraZeneca Cuts Innate-Partnered Phase 3 Trial In Head & Neck Cancer August 01, 2022 Via Benzinga AstraZeneca Drops Moderna-Partnered, Phase 2 Heart Disease Drug Candidate July 29, 2022 AstraZeneca Plc (NASDAQ: AZN) has removed a Moderna Inc (NASDAQ: MRNA)-partnered cardiovascular disease candidate from its phase 2 pipeline. Via Benzinga AstraZeneca Q2 Highlights: Profits Fall, COVID-19 Vaccine Sales Dip, Lifts Annual Sales Guidance July 29, 2022 Via Benzinga Europe's CHMP Recommends Approving AstraZeneca's Asthma, Neuromuscular Disorder Treatments July 25, 2022 Via Benzinga Merck & AstraZeneca Partnered Lynparza Fails In Late-Stage Colorectal Cancer Study July 19, 2022 Via Benzinga The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings July 19, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.